Blakey, David C.
AstraZeneca (United Kingdom)
2 papers on CoChat
Most cited papers
- Verified
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine
RNA Interference and Gene DeliveryCytokine Signaling Pathways and Interactions
Cited by 445
- Verified
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine
Protein Kinase Regulation and GTPase SignalingRNA Interference and Gene Delivery
Cited by 177
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free